Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate.
Gertz, M A; Lacy, M Q; Dispenzieri, A; Ansell, S M; Elliott, M A; Gastineau, D A; Inwards, D J; Micallef, I NM; Porrata, L F; Tefferi, A; Litzow, M R
Bone Marrow Transplantation.
34(12):1025-1031, December 2004.
(Format: HTML, PDF)